Skip to main content
. 2023 Nov 2;11(11):e006702. doi: 10.1136/jitc-2023-006702

Figure 2.

Figure 2

The intraperitoneal route of administration of MVA.scIL-12 is more efficacious than the intravenous route of administration. (A) C57BL/6 mice were challenged i.p. with 5×105 MC38 colon cancer cells. Seven days later, mice were treated i.p. with 5×107 TCID50 of MVA.empty or MVA.scIL-12 or i.v. with 5×107 TCID50 of MVA.scIL-12. The Kaplan-Meier survival curve is shown. (B) Body weight follow-up 48 hours and 96 hours after vector inoculation. (C) Platelets and (D) white blood cells 6 hours, 24 hours, or 72 hours after vector administration. (E) Concentration of IL-12 and IFN-γ 6 hour after vector inoculation in serum or in (F) peritoneal washing fluids. (G) Percentage of gp70 tetramer+ in CD8+ T lymphocytes in the spleen and the peritoneal washing fluids. (H) IFN-γ–producing cells measured by ELISpot in splenocytes stimulated with the antigen p15E604-611 or with colon cancer cells. Data are represented as mean±SEM. Two-way ANOVA followed by Sidak’s post-test. *p<0.05; **p<0.01; ANOVA, analysis of variance; ELISpot, enzyme-linked immunosorbent spot; IFN, interferon; i.p., intraperitoneal; i.v., intravenous; MVA, modified vaccinia virus Ankara; MVA.scIL-12, MVA encoding scIL-12; scIL-12, single-chain interleukin 12; TCID50, 50% tissue culture infectious dose.